Nearly 300 non-invasive diagnostic tests, are either already available in the market or under develo

Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.

 

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

Type of Tumor Marker

ctDNAcfDNACTCsExosomesOthers

Application

Diagnosis / Early DiagnosisPatient MonitoringRecurrence Monitoring

Target Cancer Indication

Breast CancerLung CancerColorectal CancerProstate CancerBladder CancerMelanomaGastric CancerPancreatic CancerOvarian CancerOthers

End Users

HospitalsResearch InstitutesOthers

Key Geographical Regions

North AmericaEuropeAsia-PacificRest of the World

The “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers.”report features the following companies, which we identified to be key players in this domain:

Amoy Diagnostics

DiaCarta

HaploX Biotechnology

NeoGenomics

QIAGEN

Swift Biosciences

Sysmex Inostics

Thermo Fisher Scientific

Press Release: Variation 3 (Format 4)

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction

 

4. Non-Invasive Cancer Screening and Diagnosis

 

5. Market Landscape

 

 

 

6. Company Profiles 

 

7. Partnerships and Collaborations

 

 

 

8. Funding and Investment Analysis

 

9. Liquid Biopsy: Initiatives of Big Pharma Players

 

10. Key Acquisition Targets

 

 

 

11. Other Non-Invasive Cancer Diagnostics

 

12. Market Sizing and Opportunity Analysis

 

13. Survey Insights

 

 

 

14. Conclusion

 

15. Executive Insights

 

 

 

16. Appendix 1: Tabulated Data

 

 

 

17. Appendix 2: List of Companies and Organizations

 

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html

  

Contact Details

 

Gaurav Chaudhary

 

+1 (415) 800 3415

 [email protected]